Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC
Authors:
- Nasim VahidfarNVNasim Vahidfar
- Saeed FarzanehfarSFSaeed Farzanehfar
- Mehrshad AbbasiMAMehrshad Abbasi
- Siroos MirzaeiSMSiroos Mirzaei
- Ebrahim S. DelpassandEDEbrahim S. Delpassand
- Farzad AbbaspourFAFarzad Abbaspour
- Yalda SalehiYSYalda Salehi
- Hans Jürgen BiersackHBHans Jürgen Biersack
- Hojjat AhmadzadehfarHAHojjat Ahmadzadehfar
Open Access
Abstract
Neuroendocrine tumours (NETs) arise from secondary epithelial cell lines in the gastrointestinal or respiratory system organs. The rate of development of these tumours varies from an indolent to an aggressive course, typically being initially asymptomatic. The identification of these tumours is difficult, particularly because the primary tumour is often small and undetectable by conventional anatomical imaging. Consequently, diagnosis of NETs is complicated and has been a significant challenge until recently. In the last 30 years, the advent of novel nuclear medicine diagnostic procedures has led to a substantial increase in NET detection. Great varieties of exclusive single photon emission computed tomography (SPECT) and positron emission tomography (PET) radiopharmaceuticals for detecting NETs are being applied successfully in clinical settings, including [111In]In-pentetreotide, [99mTc]Tc-HYNIC-TOC/TATE, [68Ga]Ga-DOTA-TATE, and [64Cu]Cu-DOTA-TOC/TATE. Among these tracers for functional imaging, PET radiopharmaceuticals are clearly and substantially superior to planar or SPECT imaging radiopharmaceuticals. The main advantages include higher resolution, better sensitivity and increased lesion-to-background uptake. An advantage of diagnosis with a radiopharmaceutical is the capacity of theranostics to provide concomitant diagnosis and treatment with particulate radionuclides, such as beta and alpha emitters including Lutetium-177 (177Lu) and Actinium-225 (225Ac). Due to these unique challenges involved with diagnosing NETs, various PET tracers have been developed. This review compares the clinical characteristics of radiolabelled somatostatin analogues for NET diagnosis, focusing on the most recently FDA-approved [64Cu]Cu-DOTA-TATE as a state-of-the art NET-PET/CT radiopharmaceutical.Keywords
This publication has 105 references indexed in Scilit:
- Synthesis of Peptide Radiopharmaceuticals for the Therapy and Diagnosis of Tumor DiseasesMolecules, 2013
- 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine TumorsJournal of Nuclear Medicine, 2011
- 111In-pentetreotide scintigraphy: procedure guidelines for tumour imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Internalized Somatostatin Receptor Subtype 2 in Neuroendocrine Tumors of Octreotide-Treated PatientsThe Journal of Clinical Endocrinology & Metabolism, 2010
- Radiolabeled somatostatin receptor antagonists are preferable to agonists forin vivopeptide receptor targeting of tumorsProceedings of the National Academy of Sciences, 2006
- Imaging of Neuroendocrine TumorsSeminars in Nuclear Medicine, 2006
- Differential Expression of the Human Somatostatin Receptor Subtypes sst1 to sst5 in Various Adrenal Tumors and Normal Adrenal GlandHormone and Metabolic Research, 2005
- Expression of Somatostatin Receptor and Effects of Somatostatin Analog on Pancreatic Endocrine TumorsSurgery Today, 2002
- Localization of neuroendocrine tumours and insulinomas using radiolabeled somatostatin analogues, 123 I‐Try3‐octreotide and 111in‐pentatreitideClinical Endocrinology, 1993
- In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in ratsLife Sciences, 1991